Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US

IMPORTANCE: Checkpoint inhibitor combination therapy represents a major advance in the first-line treatment of advanced renal cell carcinoma. Pembrolizumab-axitinib and nivolumab-ipilimumab have become standard of care options after demonstrating clinical efficacy against sunitinib in separate phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Watson, Tina R., Gao, Xin, Reynolds, Kerry L., Kong, Chung Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557509/
https://www.ncbi.nlm.nih.gov/pubmed/33052401
http://dx.doi.org/10.1001/jamanetworkopen.2020.16144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557509/
https://www.ncbi.nlm.nih.gov/pubmed/33052401
http://dx.doi.org/10.1001/jamanetworkopen.2020.16144

Ejemplares similares